Christopher M Yates
Overview
Explore the profile of Christopher M Yates including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
5539
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nishimoto A, Whaley S, Wiederhold N, Zhang Q, Yates C, Hoekstra W, et al.
Antimicrob Agents Chemother
. 2019 Aug;
63(10).
PMID: 31383660
VT-1161 and VT-1598 are promising investigational tetrazole antifungals that have shown and activity against and other fungi. is a problematic opportunistic pathogen that is associated with high mortality in invasive...
2.
Sparks S, Danger D, Hoekstra W, Leesnitzer T, Schotzinger R, Yates C, et al.
ACS Med Chem Lett
. 2019 Jul;
10(7):1056-1060.
PMID: 31312408
Excess aldosterone production and signaling are primary contributors to numerous cardiovascular disorders including primary aldosteronism and resistant hypertension. Recently, inhibition of aldosterone synthesis via the enzyme aldosterone synthase (CYP11B2) has...
3.
Nishimoto A, Wiederhold N, Flowers S, Zhang Q, Kelly S, Morschhauser J, et al.
Antimicrob Agents Chemother
. 2019 Mar;
63(6).
PMID: 30910896
The fungal Cyp51-specific inhibitors VT-1161 and VT-1598 have emerged as promising new therapies to combat fungal infections, including spp. To evaluate their activities compared to other azoles, MICs were determined...
4.
Wiederhold N, Lockhart S, Najvar L, Berkow E, Jaramillo R, Olivo M, et al.
Antimicrob Agents Chemother
. 2018 Dec;
63(3).
PMID: 30530603
is an emerging pathogen associated with significant mortality and often multidrug resistance. VT-1598, a tetrazole-based fungal CYP51-specific inhibitor, was evaluated and against Susceptibility testing was performed against 100 clinical isolates...
5.
Break T, Desai J, Healey K, Natarajan M, Ferre E, Henderson C, et al.
J Antimicrob Chemother
. 2018 May;
73(8):2089-2094.
PMID: 29788070
Background: Chronic mucocutaneous candidiasis (CMC) treatment often induces drug resistance, posing long-term challenges. A novel broad-spectrum fungal CYP51 inhibitor, VT-1598, specifically targets fungal CYP51, but not human CYP enzymes. Objectives:...
6.
Wiederhold N, Shubitz L, Najvar L, Jaramillo R, Olivo M, Catano G, et al.
Antimicrob Agents Chemother
. 2018 Feb;
62(4).
PMID: 29437615
Coccidioidal meningitis can cause significant morbidity, and lifelong antifungal therapy is often required. VT-1598 is a fungus-specific Cyp51 inhibitor that has potent activity against species. We evaluated the efficacy of...
7.
Wiederhold N, Patterson H, Tran B, Yates C, Schotzinger R, Garvey E
J Antimicrob Chemother
. 2017 Dec;
73(2):404-408.
PMID: 29190379
Background: Invasive fungal infections, including those caused by yeasts, moulds and endemic organisms, can be significant causes of morbidity and mortality in immunocompromised hosts, those with multiple comorbidities and occasionally...
8.
Yates C, Garvey E, Shaver S, Schotzinger R, Hoekstra W
Bioorg Med Chem Lett
. 2017 Jun;
27(15):3243-3248.
PMID: 28651982
While the orally-active azoles such as fluconazole and posaconazole are effective antifungal agents, they potently inhibit a broad range of off-target human cytochrome P450 enzymes (CYPs) leading to various safety...
9.
Hargrove T, Garvey E, Hoekstra W, Yates C, Wawrzak Z, Rachakonda G, et al.
Antimicrob Agents Chemother
. 2017 May;
61(7).
PMID: 28461309
Within the past few decades, the incidence and complexity of human fungal infections have increased, and therefore, the need for safer and more efficient, broad-spectrum antifungal agents is high. In...
10.
Beltran M, Yates C, Skalska L, Dawson M, Reis F, Viiri K, et al.
Genome Res
. 2016 May;
26(7):896-907.
PMID: 27197219
Polycomb repressive complex 2 (PRC2) modifies chromatin to maintain genes in a repressed state during development. PRC2 is primarily associated with CpG islands at repressed genes and also possesses RNA...